1h Free Analyst Time
The global fungal keratitis treatment market is forecasted to grow by USD 216.6 million during 2025-2030, accelerating at a CAGR of 4.5% during the forecast period. The report on the global fungal keratitis treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing awareness about eye diseases, presence of online sites selling fungal keratitis treatment drugs, increasing innovation of ocular novel drug delivery systems.
The study identifies the increase in funding for research on ophthalmic diseases as one of the prime reasons driving the global fungal keratitis treatment market growth during the next few years. Also, emerging new targets for treatment of fungal keratitis and rising demand for non-invasive fungal keratitis tests will lead to sizable demand in the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The global fungal keratitis treatment market is segmented as below:
By Route Of Administration
- Oral
- Injection
- Topical
By Distribution Channel
- Hospitals
- Drug stores
- Others
By Product Type
- Solution
- Ointment
- Others
By Region
- North America
- Europe
- Asia
- Rest of World (RoW)
- Rest of World (RoW)
The report covers the following areas:
- Global fungal keratitis treatment market sizing
- Global fungal keratitis treatment market forecast
- Global fungal keratitis treatment market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Route of Administration
9 Market Segmentation by Distribution Channel
10 Market Segmentation by Product Type
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global global fungal keratitis treatment market: A.S. Lifesciences, Alvogen Inc, Astellas Pharma Inc., Bayer AG, Cipla Inc., Gilead Sciences Inc., Glenmark Pharmaceuticals Ltd., Grevis Pharmaceuticals Pvt. Ltd., ISKON REMEDIES and GMT, Merck and Co. Inc., Novartis AG, Novo Holdings AS, Pfizer Inc., Santen Pharmaceutical Co. Ltd., Taj Pharmaceutical Ltd., Viatris Inc., Wellona Pharma.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increase in funding for research on ophthalmic diseases."
According to the report, one of the major drivers for this market is the growing awareness about eye diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A.S. Lifesciences
- Alvogen Inc
- Astellas Pharma Inc.
- Bayer AG
- Cipla Inc.
- Gilead Sciences Inc.
- Glenmark Pharmaceuticals Ltd.
- Grevis Pharmaceuticals Pvt. Ltd.
- ISKON REMEDIES and GMT
- Merck and Co. Inc.
- Novartis AG
- Novo Holdings AS
- Pfizer Inc.
- Santen Pharmaceutical Co. Ltd.
- Taj Pharmaceutical Ltd.
- Viatris Inc.
- Wellona Pharma
